4,735 reports of this reaction
1.8% of all MYCOPHENOLATE MOFETIL HYDROCHLORIDE reports
#7 most reported adverse reaction
CYTOMEGALOVIRUS INFECTION is the #7 most commonly reported adverse reaction for MYCOPHENOLATE MOFETIL HYDROCHLORIDE, manufactured by Genentech, Inc.. There are 4,735 FDA adverse event reports linking MYCOPHENOLATE MOFETIL HYDROCHLORIDE to CYTOMEGALOVIRUS INFECTION. This represents approximately 1.8% of all 257,534 adverse event reports for this drug.
MYCOPHENOLATE MOFETIL HYDROCHLORIDE has an overall safety score of 92 out of 100. Patients taking MYCOPHENOLATE MOFETIL HYDROCHLORIDE who experience cytomegalovirus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS INFECTION is a less commonly reported adverse event for MYCOPHENOLATE MOFETIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to cytomegalovirus infection, the following adverse reactions have been reported for MYCOPHENOLATE MOFETIL HYDROCHLORIDE:
The following drugs have also been linked to cytomegalovirus infection in FDA adverse event reports:
CYTOMEGALOVIRUS INFECTION has been reported as an adverse event in 4,735 FDA reports for MYCOPHENOLATE MOFETIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS INFECTION accounts for approximately 1.8% of all adverse event reports for MYCOPHENOLATE MOFETIL HYDROCHLORIDE, making it a notable side effect.
If you experience cytomegalovirus infection while taking MYCOPHENOLATE MOFETIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.